HANGZHOU, China, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Nano Labs Ltd (Nasdaq: NA) (“we,” the “Company” or “Nano Labs”), a leading fabless integrated circuit design company and product solution provider in China, today announced its unaudited financial results as of June 30, 2024 and for the first half of 2024 then ended.
Mr. Jianping Kong, Chairman and Chief Executive Officer of the Company, commented, “the first half of 2024 have shown clear signs of industry recovery and emerging market opportunities. In response to the exciting bullish market, our company has been heavily investing in the research and development of our upgraded Cuckoo series products. In May, we announced the successful mass production of the Cuckoo 3.0 chip, which significantly outperforms its predecessor, the Cuckoo 2.0 chip. This breakthrough positions us to capitalize on new market opportunities. Our company will continue to launch various models equipped with the Cuckoo 3.0 chip for different application scenarios in the second half of this year and the first half of 2025. We expect this will substantially boost our sales.
Additionally, our company is continuously improving packaging technology and IP to boost the efficiency of chip production. We are also actively developing promising AI computing and ZK computing chips.
At the same time, our iPollo Metaverse's photograph studio service is steadily advancing, with deep cooperation with various institutions and organizations. We believe this venture has the potential for explosive growth in the future.”
Mr. Bing Chen, Chief Financial Officer, commented, “for the first half of 2024, our net revenue was RMB24.7 million (US$3.5 million). In addition, the net loss was RMB59.1 million (US$8.3 million) for the six months ended June 30, 2024, compared to a net loss of RMB134.3 million in the same period of 2023. Looking ahead, we are committed to overcoming current challenges and improving our performance.”
First Half of 2024 Financial Results
Net Revenues
Net revenue was RMB24.7 million (US$3.5 million) for the first half of 2024, compared to RMB52.3 million for the same period of 2023. The decrease in net revenues was primarily due to the drop of sales volume of iPollo V1 Series. The revenues in 3D-printing products, our new products, was RMB459.2 thousand for the first half of 2024, compared to RMB22.0 thousand for the same period of 2023.
Cost of Revenues
Cost of revenues was RMB24.7 million (US$3.5 million) for the first half of 2024, compared to RMB115.2 million for the same period of 2023. The change was mainly due to the decrease in sales volume and less inventory write-down recorded.
The cost of 3D-printing products was RMB338.7 thousand for the first half of 2024, compared to RMB10.2 thousand for the same period of 2023.
Operating Expenses
Total operating expenses decreased by 20.1% to RMB58.7 million (US$8.2 million) for the first half of 2024, from RMB73.5 million for the same period of 2023.
-
Selling and marketing expenses decreased by 54.4% to RMB4.3 million (US$0.6 million) for the first half of 2024, from RMB9.5 million for the same period of 2023. The decrease in selling and marketing expenses was primarily due to the decrease in sales commission and product shipping expenses.
-
General and administrative expenses decreased by 18.0% to RMB25.5 million (US$3.6 million) for the first half of 2024, from RMB31.0 million for the same period of 2023. The decrease in general and administrative expenses was primarily due to (1) the decrease in office lease expenses mainly attributable to the relocation of the head office and (2) the decrease in employee salary expenses as the number and salaries of general and administrative staff decreased.
-
Research and development expenses decreased by 12.2% to RMB28.9 million (US$4.1 million) for the first half of 2024, from RMB33.0 million for the same period of 2023. The decrease in research and development expenses was primarily due to the decrease in salary expenses.
Loss from Operations
As a result of the foregoing, loss from operations decreased by 57.0% to RMB58.7 million (US$8.2 million) for the first half of 2024 from RMB136.4 million for the same period of 2023.
Finance Expense (Income)
Finance income was RMB0.6 million (US$0.1 million) for the first half of 2024, compared with finance expense of RMB1.6 million for the same period of 2023.
Interest expense
Interest expense was RMB2.0 million (US$0.3 million) for the first half of 2024, compared to nil for the same period of 2023. The change was due to the completion of construction in progress and cease of interest capitalization during the first half of 2024.
Net Loss
Net loss was RMB59.1 million (US$8.3 million) for the first half of 2024, compared with RMB134.3 million in the same period of 2023.
Basic and Diluted Loss Per Ordinary Share attributable to Nano Labs Ltd
Basic and diluted loss per share was RMB0.85 (US$0.12) for the first half of 2024, compared with basic and diluted loss per share of RMB2.41 for the same period of 2023.
Financial Condition
As of June 30, 2024, the Company had cash and cash equivalents of RMB23.5 million (US$3.3 million), compared with RMB48.2 million as of December 31, 2023. As of June 30, 2024, the Company had total current assets of RMB110.8 million (US$15.5 million), compared with RMB125.5 million as of December 31, 2023.
As of June 30, 2024, the Company had short-term debts, current portion of long-term debts and accounts payable in total of RMB42.8 million (US$6.0 million), compared with RMB40.3 million as of December 31, 2023. As of June 30, 2024, the Company had total current liabilities excluding advance from customers of RMB130.8 million (US$18.4 million), compared with RMB134.7 million as of December 31, 2023.
In August and September, 2024, the Company entered into related party loan agreements with two shareholders to borrow interest-free loans in the total amount of US$8.5 million (RMB60.6 million) in cash (“the Loans”) to fund the Company’s working capital. The Loans are due on the one-year anniversary of the agreement dates. The proceeds have been fully received through September 5, 2024 to September 12, 2024.
Exchange Rate
This press release contains translations of certain Renminbi (RMB) amounts into U.S. dollars (US$) solely for the convenience of the reader. Unless otherwise specified, all translations of Renminbi amounts into U.S. dollar amounts in this press release are made at RMB7.1268 to US$1.00, the central parity rate on June 30, 2024 published by the People’s Bank of China.
Non-GAAP Financial Measures
In evaluating our business, we consider and use adjusted net income/(loss) as an additional non-GAAP measure to review and assess our operating performance. The presentation of the non-GAAP financial measure is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP. We define adjusted net income/(loss) as net income/(loss) excluding share-based compensation expense.
We present the non-GAAP financial measure because they are used by our management to evaluate our operating performance and formulate business plans. Non-GAAP financial measures enable our management to assess our operating results without considering the impact of non-cash charges and non-operating items. We also believe that the use of the non-GAAP measure facilitates investors’ assessment of our operating performance.
The non-GAAP financial measure is not defined under U.S. GAAP and is not presented in accordance with U.S. GAAP. The non-GAAP financial measure has limitations as analytical tools. One of the key limitations of using the non-GAAP financial measure is that they do not reflect all items of income and expense that affect our operations. Share-based compensation expenses have been and may continue to be incurred in our business and are not reflected in the presentation of adjusted net income/(loss). Further, the non-GAAP measure may differ from the non-GAAP information used by other companies, including peer companies, and therefore their comparability may be limited.
Conference Call
The Company will host an earnings conference call to discuss its financial results at 8:30 am U.S. Eastern Time (8:30 pm Beijing Time) on September 18, 2024.
For participants who wish to join the call, please access the link provided below to complete the online registration process.
Registration Link: https://s1.c-conf.com/diamondpass/10041922-qbgnye.html
Upon registration, participants will receive the dial-in number and unique PIN, which can be used to join the conference call. If participants register and forget their PIN or lose their registration confirmation email, they may simply re-register and receive a new PIN. All participants are encouraged to dial in 15 minutes prior to the start time.
A live and archived webcast of the conference call will be accessible on the Company's investor relations website at: https://ir.nano.cn/.
A telephone replay of the call will be available until September 25, 2024 via the following dial-in details:
Dial-in Numbers:
US/Canada: | 1855 883 1031 |
Hong Kong: | 800 930 639 |
China: | 400 1209 216 |
Replay PIN: | 10041922 |
|
About Nano Labs Ltd
Nano Labs Ltd is a leading fabless integrated circuit (“IC”) design company and product solution provider in China. Nano Labs is committed to the development of high throughput computing (“HTC”) chips, high performance computing (“HPC”) chips, distributed computing and storage solutions, smart network interface cards (“NICs”) vision computing chips and distributed rendering. Nano Labs has built a comprehensive flow processing unit (“FPU”) architecture which offers solution that integrates the features of both HTC and HPC. Nano Lab’s Cuckoo series are one of the first near-memory HTC chips available in the market*. For more information, please visit the Company’s website at: ir.nano.cn.
*According to an industry report prepared by Frost & Sullivan.
Forward-Looking Statements
This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, the Company’s plan to appeal the Staff’s determination, which can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s control, which may cause the Company’s actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.
For investor and media inquiries, please contact:
Nano Labs Ltd
Email: ir@nano.cn
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
Consolidated Balance Sheets |
(Unaudited) |
| | | | | |
| As of December 31, | | As of June 30, |
| 2023 | | 2024
|
| RMB | | RMB | | US$ |
ASSETS | | | | | |
Current assets: | | | | | |
Cash and cash equivalents | 48,164,664 | | | 23,506,562 | | | 3,298,333 | |
Restricted cash | 417,990 | | | 418,201 | | | 58,680 | |
Accounts receivable, net | 1,739,065 | | | 486,251 | | | 68,229 | |
Inventories, net | 12,874,986 | | | 8,777,977 | | | 1,231,686 | |
Prepayments | 24,386,010 | | | 23,847,057 | | | 3,346,110 | |
Other current assets | 37,908,092 | | | 53,747,621 | | | 7,541,621 | |
Total current assets | 125,490,807 | | | 110,783,669 | | | 15,544,659 | |
Non-current assets: | | | | | |
Property, plant and equipment, net | 169,653,582 | | | 199,842,200 | | | 28,040,944 | |
Intangible asset, net | 47,731,288 | | | 47,238,366 | | | 6,628,272 | |
Operating lease right-of-use assets | 7,424,554 | | | 7,041,815 | | | 988,075 | |
Total non-current assets | 224,809,424 | | | 254,122,381 | | | 35,657,291 | |
| | | | | |
TOTAL ASSETS | 350,300,231 | | | 364,906,050 | | | 51,201,950 | |
| | | | | |
LIABILITIES AND SHAREHOLDERS' DEFICIT | | | | | |
Current liabilities: | | | | | |
Short-term debts | 20,000,000 | | | 20,000,000 | | | 2,806,309 | |
Current portion of long-term debts | 3,410,000 | | | 4,580,000 | | | 642,645 | |
Accounts payable | 16,875,586 | | | 18,204,768 | | | 2,554,410 | |
Advance from customers | 107,826,617 | | | 101,190,688 | | | 14,198,615 | |
Operating lease liabilities, current | 3,479,752 | | | 2,892,871 | | | 405,914 | |
Other current liabilities | 90,978,171 | | | 85,149,822 | | | 11,947,834 | |
Total current liabilities | 242,570,126 | | | 232,018,149 | | | 32,555,727 | |
Non-current liabilities: | | | | | |
Long-term debts | 120,260,783 | | | 158,660,063 | | | 22,262,455 | |
Operating lease liabilities, non-current | 3,730,672 | | | 3,938,710 | | | 552,662 | |
Total non-current liabilities | 123,991,455 | | | 162,598,773 | | | 22,815,117 | |
Total liabilities | 366,561,581 | | | 394,616,922 | | | 55,370,844 | |
Shareholders' deficit: | | | | | |
Class A ordinary shares ($0.0002 par value; 121,410,923 shares authorized; 41,927,302 and 46,275,127 shares issued as of December 31, 2023 and June 30, 2024, respectively; 37,242,359 and 41,672,037 shares outstanding as of December 31, 2023 and June 30, 2024, respectively)* | 50,106 | | | 56,398 | | | 7,914 | |
Class B ordinary shares ($0.0002 par value; 28,589,078 shares authorized; 28,589,078 shares issued and outstanding as of December 31, 2023 and June 30, 2024)* | 36,894 | | | 36,894 | | | 5,177 | |
Additional paid-in capital | 428,310,028 | | | 459,199,604 | | | 64,432,789 | |
Accumulated deficit | (452,031,693 | ) | | (509,265,433 | ) | | (71,457,798 | ) |
Statutory reserves | 6,647,109 | | | 6,647,109 | | | 932,692 | |
Accumulated other comprehensive income | 2,254,558 | | | 7,055,364 | | | 989,976 | |
Total Nano Labs Ltd shareholders' deficit | (14,732,998 | ) | | (36,270,064 | ) | | (5,089,250 | ) |
Noncontrolling interests | (1,528,352 | ) | | 6,559,192 | | | 920,356 | |
Total shareholders' deficit | (16,261,350 | ) | | (29,710,872 | ) | | (4,168,894 | ) |
| | | | | |
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT | 350,300,231 | | | 364,906,050 | | | 51,201,950 | |
|
*After giving effect of the 2-for-1 reverse stock split effective on January 31, 2024.
Consolidated Statements of Operations and Comprehensive Income (Loss) |
(Unaudited) |
| | | | | |
| For the six months ended June 30, |
| 2023 | | 2024
|
| RMB | | RMB | | US$ |
Net revenues | 52,268,716 | | | 24,739,480 | | | 3,471,331 | |
Cost of revenues | 115,167,091 | | | 24,709,417 | | | 3,467,112 | |
Gross profit (loss) | (62,898,375 | ) | | 30,063 | | | 4,219 | |
| | | | | |
Operating expenses: | | | | | |
Selling and marketing expenses | 9,501,537 | | | 4,334,564 | | | 608,206 | |
General and administrative expenses | 31,041,335 | | | 25,453,212 | | | 3,571,478 | |
Research and development expenses | 32,953,337 | | | 28,934,228 | | | 4,059,919 | |
Total operating expenses | 73,496,209 | | | 58,722,004 | | | 8,239,603 | |
| | | | | |
Loss from operations | (136,394,584 | ) | | (58,691,941 | ) | | (8,235,384 | ) |
| | | | | |
Other expenses (income): | | | | | |
Finance expenses (income) | 1,600,591 | | | (607,804 | ) | | (85,284 | ) |
Interest expenses | - | | | 2,009,586 | | | 281,976 | |
Interest income | (335,986 | ) | | (96,679 | ) | | (13,566 | ) |
Other income | (3,339,708 | ) | | (851,374 | ) | | (119,461 | ) |
Total other expenses (income) | (2,075,103 | ) | | 453,729 | | | 63,665 | |
| | | | | |
Loss before income tax provision | (134,319,481 | ) | | (59,145,670 | ) | | (8,299,049 | ) |
Income tax provision | - | | | - | | | - | |
Net loss | (134,319,481 | ) | | (59,145,670 | ) | | (8,299,049 | ) |
Less: net loss attributable to noncontrolling interests | - | | | (1,911,930 | ) | | (268,273 | ) |
Net loss attributable to Nano Labs Ltd | (134,319,481 | ) | | (57,233,740 | ) | | (8,030,776 | ) |
| | | | | |
Comprehensive income (loss): | | | | | |
Net loss | (134,319,481 | ) | | (59,145,670 | ) | | (8,299,049 | ) |
Other comprehensive income: | | | | | |
Foreign currency translation adjustment | 1,771,255 | | | 4,800,723 | | | 673,616 | |
Total comprehensive loss | (132,548,226 | ) | | (54,344,947 | ) | | (7,625,433 | ) |
Comprehensive loss attributable to noncontrolling interests | - | | | (1,912,013 | ) | | (268,285 | ) |
Comprehensive loss attributable to Nano Labs Ltd | (132,548,226 | ) | | (52,432,934 | ) | | (7,357,148 | ) |
| | | | | |
Net loss per ordinary share attributable to Nano Labs Ltd | | | | | |
Basic* | (2.41 | ) | | (0.85 | ) | | (0.12 | ) |
Diluted* | (2.41 | ) | | (0.85 | ) | | (0.12 | ) |
| | | | | |
Weighted average number of shares used in per share calculation: | | | | | |
Basic* | 55,748,336 | | | 67,666,712 | | | 67,666,712 | |
Diluted* | 55,748,336 | | | 67,666,712 | | | 67,666,712 | |
|
*After giving effect of the 2-for-1 reverse stock split effective on January 31, 2024.
Non-GAAP Reconciliation |
(Unaudited) |
| For the Six Months Ended June 30, |
| 2023
| | 2024
|
| RMB | RMB | US$ |
Net loss | (134,319,481 | ) | | (59,145,670 | ) | (8,299,049 | ) |
Add: | | | |
Share-based compensation expenses | 137,598 | | | 285,507 | | 40,061 | |
Non-GAAP adjusted net loss | (134,181,883 | ) | | (58,860,163 | ) | (8,258,988 | ) |